Research programme: cell cycle inhibitors - Cyclacel

Drug Profile

Research programme: cell cycle inhibitors - Cyclacel

Alternative Names: Anti-HIV therapeutics research programme - Cyclacel; Research programme: anti-HIV therapeutics - Cyclacel

Latest Information Update: 14 Jul 2014

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Cyclacel Pharmaceuticals
  • Class
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Suspended HIV infections

Most Recent Events

  • 28 Mar 2006 Xcyte Therapies has merged with Cyclacel to form Cyclacel Pharmaceuticals
  • 26 May 2005 This programme is still in active development
  • 13 Jul 2004 Preclinical trials in HIV infections treatment in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top